Chemical Compound Review:
Tomelukast 1-[2-hydroxy-3-propyl-4-[4- (2H-tetrazol-5...
Synonyms:
Tomelukastum, SureCN3944, CHEMBL162358, AG-J-77739, SureCN5325407, ...
- Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883. Eacho, P.I., Lanier, T.L., Brodhecker, C.A. Carcinogenesis (1991)
- H-ras 61st codon activation in archival proliferative hepatic lesions isolated from female B6C3F1 mice exposed to the leukotriene D4-antagonist, LY171883. Helvering, L.M., Richardson, F.C., Horn, D.M., Rexroat, M.A., Engelhardt, J.A., Richardson, K.K. Carcinogenesis (1994)
- Enhanced activity of Ca2+-activated K+ channels by 1-[2-hydroxy-3-propyl-4-[(1H-tetrazol-5-yl)butoxyl]phenyl] ethanone (LY-171883) in neuroendocrine and neuroblastoma cell lines. Li, P.C., Liang, J.T., Huang, H.T., Lin, P.H., Wu, S.N. J. Cell. Physiol. (2002)
- Protective effect of a selective leukotriene antagonist in endotoxemia in the rat. Cook, J.A., Wise, W.C., Halushka, P.V. J. Pharmacol. Exp. Ther. (1985)
- Hemodynamic effects of heat-killed group B beta-hemolytic streptococcus in newborn lambs: role of leukotriene D4. Schreiber, M.D., Covert, R.F., Torgerson, L.J. Pediatr. Res. (1992)
- Potentiation of TNF-alpha-stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells. Scholz-Pedretti, K., Gans, A., Beck, K.F., Pfeilschifter, J., Kaszkin, M. J. Am. Soc. Nephrol. (2002)
- Binding of radiolabeled high affinity antagonist to leukotriene D4 receptor in guinea pig lung membranes: interconversion of agonist-receptor binding affinity states. O'Sullivan, B.P., Mong, S. Mol. Pharmacol. (1989)
- Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Eacho, P.I., Foxworthy, P.S., Johnson, W.D., Hoover, D.M., White, S.L. Toxicol. Appl. Pharmacol. (1986)
- Protective effect of peptide leukotriene antagonist on renal failure induced by a tourniquet in rabbits. Tanaka, T., Kita, T., Liu, R., Tanaka, N. Forensic Sci. Int. (1995)
- Endotoxemia in rats--influence of lipoxygenase blocker versus leukotriene receptor antagonist (BW755C vs LY171883). Bahrami, S., Paul, E., Redl, H., Schlag, G., Mihm, F. Prog. Clin. Biol. Res. (1988)
- Adrenalectomy exacerbates paw edema without interfering with desensitization induced by PAF-acether in rats. Silva, P.M., Martins, M.A., Castro-Faria-Neto, H.C., Cordeiro, R.S., Vargaftig, B.B. Braz. J. Med. Biol. Res. (1988)
- Leukotrienes D4 and E4 produced in myocardium impair coronary flow and ventricular function after two hours of global ischaemia in rat heart. Lee, C.C., Appleyard, R.F., Byrne, J.G., Cohn, L.H. Cardiovasc. Res. (1993)
- Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion. Hock, C.E., Beck, L.D., Papa, L.A. Cardiovasc. Res. (1992)
- Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. Phillips, G.D., Rafferty, P., Robinson, C., Holgate, S.T. J. Pharmacol. Exp. Ther. (1988)
- Effect of the peroxisome proliferator LY171883 on triglyceride accumulation in rats fed a fat-free diet. Foxworthy, P.S., Eacho, P.I. Biochem. Pharmacol. (1991)
- Interaction of LY171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver. Cannon, J.R., Eacho, P.I. Biochem. J. (1991)
- LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist. Fleisch, J.H., Rinkema, L.E., Haisch, K.D., Swanson-Bean, D., Goodson, T., Ho, P.P., Marshall, W.S. J. Pharmacol. Exp. Ther. (1985)
- Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Foxworthy, P.S., White, S.L., Hoover, D.M., Eacho, P.I. Toxicol. Appl. Pharmacol. (1990)
- Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Rovati, G.E., Giovanazzi, S., Mezzetti, M., Nicosia, S. Biochem. Pharmacol. (1992)
- Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation. Nieves, D., Moreno, J.J. Biochem. Pharmacol. (2006)
- Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Yamakawa, K., Hosoi, M., Koyama, H., Tanaka, S., Fukumoto, S., Morii, H., Nishizawa, Y. Biochem. Biophys. Res. Commun. (2000)
- Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Downie, M.M., Sanders, D.A., Maier, L.M., Stock, D.M., Kealey, T. Br. J. Dermatol. (2004)
- Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Grau, R., Punzón, C., Fresno, M., Iñiguez, M.A. Biochem. J. (2006)
- Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus. Lawrence, J.W., Kroll, D.J., Eacho, P.I. J. Lipid Res. (2000)